STOCK TITAN

FMR LLC and Abigail Johnson disclose 7.2% Moderna (MRNA) stake in Schedule 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

FMR LLC has filed a Schedule 13G reporting beneficial ownership of 27,961,310.82 shares of Moderna Inc. common stock, representing 7.2% of the class as of the stated event date. All of these shares are reported with sole dispositive power and no shared voting or dispositive power.

Abigail P. Johnson is also listed as a reporting person, with the same 27,961,310.82 shares beneficially owned through sole dispositive power and no voting or shared dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Moderna.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



FMR LLC
Signature:Stephanie J. Brown
Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:02/04/2026
Abigail P. Johnson
Signature:Stephanie J. Brown
Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:02/04/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What stake in Moderna (MRNA) does FMR LLC report on this Schedule 13G?

FMR LLC reports beneficial ownership of 27,961,310.82 shares of Moderna common stock, representing 7.2% of the outstanding class. These shares are held with sole dispositive power and no shared voting or dispositive power, indicating a significant institutional position.

How is Abigail P. Johnson involved in the Moderna (MRNA) ownership reported here?

Abigail P. Johnson is a separate reporting person, showing beneficial ownership of 27,961,310.82 shares of Moderna common stock through sole dispositive power. She reports no voting power and no shared dispositive power, aligning her reported interest with the FMR LLC position.

Is the Moderna (MRNA) stake held to influence control of the company?

The filing certifies the Moderna securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also states they are not held in connection with any transaction aimed at gaining control, other than certain nomination activities.

What percentage of Moderna (MRNA) common stock does this Schedule 13G represent?

The Schedule 13G reports that 7.2% of Moderna’s common stock class is beneficially owned. This percentage is tied to the 27,961,310.82 shares reported, giving investors a clear view of the scale of FMR LLC’s and Abigail P. Johnson’s disclosed holdings.

Who has rights to dividends or sale proceeds from FMR LLC’s Moderna (MRNA) shares?

The filing notes that one or more other persons are known to have rights to receive dividends or sale proceeds from Moderna common stock. However, no single other person’s interest relates to more than five percent of the total outstanding Moderna common stock.

What does sole dispositive power mean in this Moderna (MRNA) Schedule 13G?

Sole dispositive power means the reporting person can decide whether to sell or otherwise dispose of the 27,961,310.82 Moderna shares without needing another party’s consent. The filing shows no shared dispositive power, highlighting centralized control over potential dispositions.
Moderna

NASDAQ:MRNA

MRNA Rankings

MRNA Latest News

MRNA Latest SEC Filings

MRNA Stock Data

16.71B
361.71M
7.24%
74.89%
15.38%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE